Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 2:2019:1730978.
doi: 10.1155/2019/1730978. eCollection 2019.

Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches

Affiliations
Review

Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches

Vasilis Paspaliaris et al. Stem Cells Int. .

Abstract

Osteoporosis is a systemic disease that affects the skeleton, causing reduction of bone density and mass, resulting in destruction of bone microstructure and increased risk of bone fractures. Since osteoporosis is a disease affecting the elderly and the aging of the world's population is constantly increasing, it is expected that the incidence of osteoporosis and its financial burden on the insurance systems will increase continuously and there is a need for more understanding this condition in order to prevent and/or treat it. At present, available drug therapy for osteoporosis primarily targets the inhibition of bone resorption and agents that promote bone mineralization, designed to slow disease progression. Safe and predictable pharmaceutical means to increase bone formation have been elusive. Stem cell therapy of osteoporosis, as a therapeutic strategy, offers the promise of an increase in osteoblast differentiation and thus reversing the shift towards bone resorption in osteoporosis. This review is focused on the current views regarding the implication of the stem cells in the cellular and physiologic mechanisms of osteoporosis and discusses data obtained from stem cell-based therapies of osteoporosis in experimental animal models and the possibility of their future application in clinical trials.

PubMed Disclaimer

References

    1. Sale J. E. M., Beaton D., Bogoch E. Secondary prevention after an osteoporosis-related fracture: an overview. Clinics in Geriatric Medicine. 2014;30(2):317–332. doi: 10.1016/j.cger.2014.01.009. - DOI - PubMed
    1. Sáez-López P., Etxebarria-Foronda I., Mesa Lampre M. P., Alonso García N., Sánchez Hernández N. Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. Revista Española de Geriatría y Gerontología. 2019;54(3):156–167. doi: 10.1016/j.regg.2018.11.007. - DOI - PubMed
    1. Wade S. W., Strader C., Fitzpatrick L. A., Anthony M. S., O’Malley C. D. Estimating prevalence of osteoporosis: examples from industrialized countries. Archives of Osteoporosis. 2014;9(1):p. 182. doi: 10.1007/s11657-014-0182-3. - DOI - PubMed
    1. Kanis J. A., McCloskey E. V., Johansson H., Oden A., Melton L. J., III, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467–475. doi: 10.1016/j.bone.2007.11.001. - DOI - PubMed
    1. Dempster D. W. Osteoporosis and the burden of osteoporosis-related fractures. American Journal of Managed Care. 2011;17(Supplement 6):S164–S169. - PubMed

LinkOut - more resources